Only 15,000 scripts per month would see BOT net sales at about $100m. I don’t think it’ll be too hard to take that market share from Qbrexza and Botox. Drysol is way cheaper, but also way less effective. I reckon BOT will probably attract a fair share of otherwise untreated sufferers too! $100m net with a 20xPE (like NEU) would see BOT above $1, just on Sofdra alone.
BOT - Anything but charting, page-6801
-
- There are more pages in this discussion • 2,679 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.005(1.33%) |
Mkt cap ! $669.7M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.0¢ | 36.5¢ | $960.8K | 2.588M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 35 | 527761 | 36.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.0¢ | 280228 | 15 |
View Market Depth
| Last trade - 14.29pm 30/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |